General Pharmaceutical Council (GPhC) - News updates

Valproate National Patient Safety Alert

The Medicines and Healthcare products Regulatory Agency (MHRA) have issued a Valproate National Patient Safety Alert in advance of new regulatory measure being introduced from January 2024. The alert calls on Integrated Care Boards (in England) and Health Boards (in Scotland and Wales) to designate a new or existing group to prepare for and co-ordinate the implementation of the new regulatory measures for oversight of prescribing valproate to new patients and existing female patients.

Contact centre on 16 November 2023

The contact centre will be closed from 11:15am on Thursday 16 November for training purposes. Lines will re-open at 2:15pm on the same day. During this time please email any enquiries to

​​GPhC Council agrees to increase fees​

The General Pharmaceutical Council (GPhC) has agreed to increase fees by 7.5% from April 2024.  The GPhC Council has taken the difficult decision to increase fees after careful consideration at its meeting on 9 November 2023. Fees for individual registrants have been frozen since 2019 and the current fees remain lower than they were in 2011. Fees for premises have not increased since 2021.  This means that from April 2024: 

GPhC Council meeting on 9 November 2023

The Council of the GPhC will be meeting on Thursday 9 November. Please contact our Council secretary by 4pm on Wednesday 8 November 2023, if you would like to attend the meeting. 

Update: issues with myGPhC

We are very sorry for the technical issues registrants have been experiencing with My GPhC. We are working to resolve any outstanding problems as quickly as possible. We will provide a further update on the situation tomorrow. In the meantime, we have extended the deadline for those due to submit their renewal or revalidation by 31 October 2023 to 11:59pm on Tuesday 7 November 2023.

myGPhC portal now available again

myGPhC is currently up and running, but you may experience delays. We are still monitoring the situation and trying to fix the issue as a priority. We apologise for the inconvenience caused and will continue to provide updates.  

New Chief Pharmacy Officer and Chief Enforcement Officer announced for GPhC

The GPhC is delighted to welcome Roz Gittins as Chief Pharmacy Officer and Deputy Registrar, and Dionne Spence as Chief Enforcement Officer and Deputy Registrar.

GPhC publishes diversity data of professionals involved in its Fitness to Practise process

The GPhC has today published an initial analysis of diversity data of professionals involved in its Fitness to Practise process in 2021/22, looking specifically at concerns received and investigated, statutory outcomes of closed concerns and progression through the process. 

New rules on the way medicines containing valproate are dispensed come into force

Medicines containing valproate must now be sold or supplied in the manufacturer’s original outer packaging, with warnings about the risks of taking the medication during pregnancy.     Children born to women who take valproate during pregnancy are at significant risk of birth defects and persistent developmental disorders. As such, it is vital that women and girls are dispensed valproate safely.  

GPhC joins RPS working group to address differential attainment in education and training

The GPhC has joined a new group, led by the Royal Pharmaceutical Society (RPS) to address the differential attainment and awarding gap experienced by black pharmacy students and Foundation Trainees. The RPS has today published a statement about the working group, which includes plans for collaborative work to develop recommendations and actions to improve the differential attainment and awarding gap in a meaningful and sustainable way.